TBVI
By
TBVI,
IAVI
Published: June 14, 2021, 2:35 p.m.·
Tags:
Vaccines
Read More →
By
TBVI
Published: Jan. 20, 2021, 9:03 a.m.·
Tags:
Vaccines
To fight tuberculosis, better vaccination strategies are needed. Two recent publications demonstrate the positive effects of alternative mucosal routes of administration on the ensuing innate and adaptive immune responses induced by live mycobacterial vaccines.
Read More →
By
TBVI
Published: Jan. 11, 2021, 8:36 p.m.·
Tags:
Vaccines,
Research and development
The Amsterdam Institute for Global Health and Development published the Global roadmap for research and development for TB vaccines as a draft document for public consultation, developed with key stakeholders.
Read More →
By
TBVI
Published: Aug. 30, 2019, 11:45 p.m.·
Tags:
Vaccines,
Pediatrics
First trial of a new live attenuated Mycobacterium tuberculosis vaccine in infants.
Read More →
By
TBVI
Published: Sept. 24, 2018, 10:10 a.m.·
Tags:
Vaccines
In the effort to eradicate tuberculosis as one of the world’s most deadly diseases, novel TB vaccines will be an important part of the solution. There is a pipeline of new TB vaccines that requires a global and comprehensive coordination of efforts with defined stages of development and criteria for progression of individual vaccine candidates.
Read More →
By
TBVI
Published: June 22, 2016, 12:53 p.m.·
Tags:
Vaccines
TuBerculosis Vaccine Initiative (TBVI) is recruiting an early to mid-career dynamic person for the position of Scientific communications officer.
Read More →
By
Biofabri,
University of Zaragoza,
SATVI,
TBVI
Published: Sept. 20, 2015, 8:04 p.m.·
Tags:
Vaccines,
Scientific research
The clinical trial will be conducted by South African Tuberculosis Vaccine Initiative (SATVI).
Biofabri, biotechnology company focusing on human health vaccines, will sponsor the Phase 1B clinical trial.
Read More →
By
TBVI
Published: Aug. 15, 2014, 8:03 p.m.·
Tags:
Scientific research,
Vaccines
TBVI's research partner Norwegian University of Life Sciences receives a research grant of 10.2 million Norwegian Crowns (1.25 million euro) for the development of new TB vaccines. The grant is awarded by the Norwegian Programme for Global Health and Vaccination Research (GLOBVAC) for the period 1 September 2014- 31 August 2018. The research activitities will be executed in close collaboration with the TBVI network.
Read More →
By
TBVI,
Aeras
Published: June 12, 2013, 3:10 p.m.·
Tags:
None
Making new TB vaccines available to the world over the next 10-15 years is estimated to cost approximately €600 million, utilizing a highly efficient portfolio approach and adequate funding.
Read More →
Page 1 of 1 · Total posts: 9
1